fda approves first oral glp-1 obesity drug august 1 2025 pill for from Wegovy maker Novo Nordisk Novo's Wegovy becomes first GLP-1

1 In parallel, semaglutide will become generic in some key markets from 2026 onward (e.g., India, China, Brazil), and pressure from compounding pharmacies to meet unmet demand for GLP1 therapies adds another layer of complexity and competition to the evolving treatment landscape

A review of 30 randomized controlled trials that included 1,736 people with type 2 diabetes or non-alcoholic fatty liver disease found that treatment with GLP-1 agonists significantly reduced both visceral and liver fat

HbA1c: Four studies (200 participants) reported changes in HbA1c of which due to lack of common comparator, only two studies could be pooled (Electronic Supplementary Fig

The pigs were male, with an average weight of 40 kg

LIR was found to stimulate the thermogenesis of brown adipose tissue and the browning of adipose cells, independent of the intake of nutrients